Fei Teng

3.2k total citations · 1 hit paper
39 papers, 1.5k citations indexed

About

Fei Teng is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Fei Teng has authored 39 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Fei Teng's work include CRISPR and Genetic Engineering (9 papers), Cancer Mechanisms and Therapy (4 papers) and RNA Interference and Gene Delivery (3 papers). Fei Teng is often cited by papers focused on CRISPR and Genetic Engineering (9 papers), Cancer Mechanisms and Therapy (4 papers) and RNA Interference and Gene Delivery (3 papers). Fei Teng collaborates with scholars based in China, United States and Japan. Fei Teng's co-authors include Qi Zhou, Qingqin Gao, Tongtong Cui, Lu Guo, Kai Xu, Wei Li, Wei Li, Jing Li, Guihai Feng and Tianda Li and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Fei Teng

36 papers receiving 1.4k citations

Hit Papers

CDetection: CRISPR-Cas12b-based DNA detection with sub-at... 2019 2026 2021 2023 2019 50 100 150 200 250

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fei Teng China 16 1.2k 240 188 164 107 39 1.5k
Guillermo Aquino‐Jarquín Mexico 18 768 0.7× 338 1.4× 102 0.5× 64 0.4× 26 0.2× 43 1.0k
Yi-Min Zheng China 11 496 0.4× 230 1.0× 74 0.4× 51 0.3× 13 0.1× 21 930
Ana B. Herrero Spain 21 729 0.6× 142 0.6× 98 0.5× 48 0.3× 89 0.8× 42 1.1k
L. Tong United Kingdom 15 790 0.7× 89 0.4× 85 0.5× 72 0.4× 38 0.4× 27 1.2k
Alexander Lezhava Japan 19 821 0.7× 198 0.8× 96 0.5× 134 0.8× 115 1.1× 48 1.2k
Dickson Adah China 15 288 0.2× 92 0.4× 43 0.2× 76 0.5× 14 0.1× 22 714
Claire E. Senner United Kingdom 21 1.2k 1.0× 142 0.6× 295 1.6× 45 0.3× 44 0.4× 23 1.6k
M. Lucrecia Alvarez United States 17 1.2k 1.0× 657 2.7× 84 0.4× 62 0.4× 182 1.7× 27 1.5k
Markus Düchler Poland 17 601 0.5× 221 0.9× 19 0.1× 53 0.3× 33 0.3× 22 892
Sunil K. Malonia United States 14 572 0.5× 176 0.7× 94 0.5× 47 0.3× 71 0.7× 25 1.0k

Countries citing papers authored by Fei Teng

Since Specialization
Citations

This map shows the geographic impact of Fei Teng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Teng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Teng more than expected).

Fields of papers citing papers by Fei Teng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fei Teng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Teng. The network helps show where Fei Teng may publish in the future.

Co-authorship network of co-authors of Fei Teng

This figure shows the co-authorship network connecting the top 25 collaborators of Fei Teng. A scholar is included among the top collaborators of Fei Teng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fei Teng. Fei Teng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lin, Mingen, Fei Teng, Yan Ma, et al.. (2025). TET2 orchestrates YAP signaling to potentiate targetable vulnerability in hepatocellular carcinoma. Cell Death and Disease. 16(1). 438–438.
2.
Wang, Shengnan, Zexu Li, Xiaofeng Wang, et al.. (2025). Chemoresistance mechanisms to 5-Fluorouracil and reversal strategies in lung and breast cancer. Scientific Reports. 15(1). 6074–6074. 2 indexed citations
4.
Liu, Jiayu, Fei Teng, Haifeng Qin, et al.. (2025). Effect of the number of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer. Translational Lung Cancer Research. 14(4). 1408–1417. 1 indexed citations
5.
Zhang, Haijiao, Jiahui Lin, Shaoqin Zheng, et al.. (2024). CDKL3 is a targetable regulator of cell cycle progression in cancers. Journal of Clinical Investigation. 134(16). 4 indexed citations
6.
Wang, Xiaojuan, et al.. (2023). A dual amplification strategy integrating entropy-driven circuit with Cas14a for sensitive detection of miRNA-10b. Sensors and Actuators B Chemical. 397. 134666–134666. 3 indexed citations
7.
Wang, Xiang, Zhiqun He, Xinyue Xu, et al.. (2023). Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis. Microbiology Spectrum. 11(5). e0472122–e0472122. 4 indexed citations
8.
Yao, Yingjia, Yunhan Zhang, Zexu Li, et al.. (2023). A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism. Biochemical and Biophysical Research Communications. 675. 113–121. 2 indexed citations
9.
Cheng, Xiaolong, Zexu Li, Zihan Li, et al.. (2023). Modeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches. Nature Communications. 14(1). 752–752. 38 indexed citations
10.
Li, Zexu, Yingjia Yao, Xiaolong Cheng, et al.. (2021). A computational framework of host-based drug repositioning for broad-spectrum antivirals against RNA viruses. iScience. 24(3). 102148–102148. 13 indexed citations
11.
Zhang, Yanfang, Dan Li, Qi Yan, et al.. (2021). Weight Loss Improves Pregnancy and Livebirth Outcomes in Young Women with Early-Stage Endometrial Cancer and Atypical Hyperplasia. Cancer Management and Research. Volume 13. 5711–5722. 13 indexed citations
12.
Teng, Fei, Tongtong Cui, Qingqin Gao, et al.. (2019). Artificial sgRNAs engineered for genome editing with new Cas12b orthologs. Cell Discovery. 5(1). 23–23. 16 indexed citations
13.
Teng, Fei, Jing Li, Tongtong Cui, et al.. (2019). Enhanced mammalian genome editing by new Cas12a orthologs with optimized crRNA scaffolds. Genome biology. 20(1). 15–15. 82 indexed citations
14.
Teng, Fei, Lu Guo, Tongtong Cui, et al.. (2019). CDetection: CRISPR-Cas12b-based DNA detection with sub-attomolar sensitivity and single-base specificity. Genome biology. 20(1). 132–132. 275 indexed citations breakdown →
15.
Teng, Fei, Tongtong Cui, Guihai Feng, et al.. (2018). Repurposing CRISPR-Cas12b for mammalian genome engineering. Cell Discovery. 4(1). 63–63. 200 indexed citations
16.
Xu, Zhiyuan, Yi‐Ping Wang, Chunli Zhang, et al.. (2017). Aqueous Huaier Extract Suppresses Gastric Cancer Metastasis and Epithelial to Mesenchymal Transition by Targeting Twist. Journal of Cancer. 8(18). 3876–3886. 35 indexed citations
17.
Gao, Jinping, Wenyan Tian, Fei Teng, et al.. (2017). Endometrial cancer with congenital uterine anomalies: 3 case reports and a literature review. Cancer Biology & Therapy. 18(3). 123–131. 13 indexed citations
18.
Wang, Yingmei, Yufang Yang, Fei Teng, Huiying Zhang, & Fengxia Xue. (2014). Pure nongestational uterine choriocarcinoma in a postmenopausal Chinese woman confirmed with short tandem repeat analysis. American Journal of Obstetrics and Gynecology. 211(1). e1–e3. 16 indexed citations
19.
Teng, Fei, Kai Xia, Zhongwei Li, et al.. (2009). Genome-wide mapping of SMAD target genes reveals the role of BMP signaling in embryonic stem cell fate determination. Genome Research. 20(1). 36–44. 99 indexed citations
20.
Teng, Fei, Yaoying Zeng, Xiu−Yan Huang, et al.. (2008). [Effect of icariin on intermediate and advanced activation of murine T lymphocytes in vitro].. PubMed. 24(11). 1059–61. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026